ClinicalTrials.gg
CompletedNCT03311009Updated Nov 24, 2017

A Study With GLPG1972 in Osteoarthritis Subjects

A Phase 1 interventional study of GLPG1972 cohort 1 and GLPG1972 cohort 2 in Osteoarthritis, sponsored by Galapagos NV. Completed at 1 site in United States. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-11-24.

Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2017, 9 years ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled May 2017, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.

Enrollment
672nd of 832
30 · median 100
Started
2017
with 44 others
Phase 1
45 of 1,029
6 open now
Registered
698th of 1,029
by date

Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 672nd largest by enrollment of the 832 interventional ones that give a count, is one of 45 that started in 2017, is one of 45 in phase 1, and was the 698th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,029 studies in Osteoarthritis with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo. Per cohort, 10 subjects will be randomized in a 4:1 allocation ratio to active treatment with GLPG1972 or matching placebo. In each cohort, OA subjects will be stratified for age (50- 64 years and 65-75 years) with a minimum of 2 of each sex per age group.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects of non-, 50-75 years of age on the date of signing the Form (ICF), inclusive extremes.
  2. Diagnosis of OA (knee and/or hip) made by their physician based on symptoms, clinical signs and documented historical imaging evidence.
  3. A (BMI) between 18.0 and 34.9 kg/m2, inclusive extremes.
  4. Judged to be in age-appropriate good health by the investigator based upon the results of a medical history, physical examination, vital signs and 12-lead , and fasting clinical laboratory profile.
  5. Subjects with a stable chronic illness at least 3 months will be accepted subject to the investigator's judgment.

Exclusion criteria

Exclusion Criteria:

  1. Administration of intraarticular injections or hyaluronan injections in the last 3 months prior to study screening.
  2. Subjects who underwent or are on a waiting list for total hip or knee replacement and any other surgery planned during the study (up to Day 50).
  3. Known to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
  4. Positive serology for or antibody or history of hepatitis from any cause with the exception of hepatitis A.
  5. History of or a current condition.
  6. serious, per investigator's discretion, and/or unstable illness in the 3 months before screening
  7. Renal function with an estimated \< 60 mL/min based on the Cockcroft-Gault formula. Retesting is allowed once (see Section 5.2).
  8. Use of verapamil, diltiazem, amitriptyline, warfarin, acenocoumarol, phenobarbital and phenytoin, within 4 weeks before first study drug administration
  9. Consumption of herbal medications that are strong inhibitors and/or inducers of CYPs (e.g., St. John's Wort) and grapefruit/grapefruit products, Seville oranges, or any poppy seed, within 7 days prior to the first study drug administration.
  10. History of solid organ or hematopoietic cell transplantation.
  11. History of within the past 5 years.
  12. Clinically significant abnormalities detected on 12-lead of either rhythm or conduction (e.g., ≥ 450 ms for males and QTcF ≥ 470 ms for females, or a known long QT syndrome).
  13. Significant blood loss (including blood donation [> 450 mL]), or transfusion of any blood product within 12 weeks prior to screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    GLPG1972

    Drug: GLPG1972 cohort 1 · Drug: GLPG1972 cohort 2 · Drug: GLPG1972 cohort 3

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Difference between GLPG1972 treated subjects and placebo subjects in the number of Adverse Events

    To assess safety and tolerability of GLPG1972 in OA patients

    Time frame: From screening until the final follow up visit (day 50)

  2. Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal vital signs

    To assess safety and tolerability of GLPG1972 in OA patients

    Time frame: From screening until the final follow up visit (day 50)

  3. Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal clinical laboratory evaluations

    To assess safety and tolerability of GLPG1972 in OA patients

    Time frame: Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50)

  4. Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal physical examination

    To assess safety and tolerability of GLPG1972 in OA patients

    Time frame: Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50

  5. Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal ECG

    To assess safety and tolerability of GLPG1972 in OA patients

    Time frame: Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50)

  6. Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal Holter assessment

    To assess safety and tolerability of GLPG1972 in OA patients

    Time frame: Day -1 to days 1 and Day 10 to day 11

  7. The maximum observed plasma concentration of GLPG1972 (Cmax)

    To assess PK of GLPG1972 in OA patients

    Time frame: Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43

  8. The time (tmax) to reach Cmax of GLPG1972

    To assess PK of GLPG1972 in OA patients

    Time frame: Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43

  9. The plasma concentration of GLPG1972 24 after the last dose

    To assess PK of GLPG1972 in OA patients

    Time frame: Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43

  10. The area under the plasma concentration time curve from time 0 until the last quantifieble dose

    To assess PK of GLPG1972 in OA patients

    Time frame: Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43

Secondary outcomes

  1. Percentage reduction of neo-epitope ARGS vs baseline

    To assess PD of GLPE1972 in OA patients

    Time frame: Days 1, 3, 6, 8, 10, 15, 22, 29, 43 and the final follow up visit (day 50)

07

Study locations

1 site
  • Covance Daytona Beach
    Daytona Beach, Florida 32117, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Oct 2017, 5 months.

Of 35 industry-sponsored phase 1 interventional studies under Osteoarthritis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 5 months is below that.

Counting every sponsor, half of 58 studies reached it within 20 months; a quarter within 9 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2017
First posted
Oct 16, 2017
StartActual
May 15, 2017
Primary completionActual
Oct 25, 2017
CompletionActual
Oct 25, 2017
Last update
Nov 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03311009
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Oct 16, 2017
Start date
May 15, 2017
Primary completion
Oct 25, 2017
Completion
Oct 25, 2017
Last update
Nov 24, 2017

Study contacts

Ann Fieuw, MD, MSc
study director · Galapagos NV

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aldumastat

Start the discussion